Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akers Biosciences, Inc.    AKER

AKERS BIOSCIENCES, INC.

(AKER)
  Report
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
2.69(c) 2.85(c) 2.83(c) 3.06(c) 2.78(c) Last
222 868 436 188 405 274 1 812 055 648 187 Volume
-2.89% +5.95% -0.70% +8.13% -9.15% Change
More quotes
Financials (USD)
Sales 2018 1,67 M - -
Net income 2018 -10,8 M - -
Net cash position 2018 5,46 M - -
P/E ratio 2018 -1,22x
Yield 2018 -
Sales 2019 1,58 M - -
Net income 2019 -3,89 M - -
Net cash position 2019 9,68 M - -
P/E ratio 2019 -0,50x
Yield 2019 -
Capitalization 24,6 M 24,6 M -
EV / Sales 2018 5,19x
EV / Sales 2019 -3,83x
Nbr of Employees 12
Free-Float 84,1%
More Financials
Company
Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company’s product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin... 
More about the company
All news about AKERS BIOSCIENCES, INC.
01/25AKERS BIOSCIENCES : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
2020AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..
BU
2020AKERS BIOSCIENCES : ' Proposed Merger Partner MyMD Pharmaceuticals Announces Iss..
BU
2020AKERS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020REMINDER : Akers Biosciences Schedules Conference Call to Discuss Merger with My..
BU
2020AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..
BU
2020AKERS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
2020AKERS BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
2020AKERS BIOSCIENCES : Entry into a Material Definitive Agreement, Unregistered Sal..
AQ
2020AKERS BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Unregister..
AQ
2020AKERS MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Wheth..
BU
2020Akers Biosciences, MyMD Pharmaceuticals Ink Merger Agreement
MT
2020AKERS BIOSCIENCES : and MyMD Pharmaceuticals Sign Definitive Merger Agreement
BU
More news
News in other languages on AKERS BIOSCIENCES, INC.

- No features available -

More news
Chart AKERS BIOSCIENCES, INC.
Duration : Period :
Akers Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKERS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Managers and Directors
NameTitle
Christopher C. Schreiber President & Chief Executive Officer
Joshua Nathaniel Silverman Chairman
Stuart Benson Chief Financial Officer
Bill Joe White Independent Non-Executive Director
Robert C. Schroeder Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AKERS BIOSCIENCES, INC.39.70%27
ABBOTT LABORATORIES4.38%196 578
MEDTRONIC PLC-4.81%157 148
BECTON, DICKINSON AND COMPANY0.27%75 142
HOYA CORPORATION-3.92%48 957
ALIGN TECHNOLOGY, INC.-4.63%42 193